| abstract |
The present application generally relates to methods for preventing or treating bleeding and / or coagulation in individuals in need of preventing or treating bleeding and / or coagulation, and compositions for use in such methods. Such methods include FVa, preferably APC resistant FVa (such as Super FVa), alone or FVIIa, preferably rhFVIIa (NovoSeven® or another FVIIa with increased activity or increased half-life, etc. ) In combination with. When administered in combination, FVa and FVIIa may be used in subjects in need of treating or preventing bleeding or hypocoagulability, such as genetic disorders such as hemophilia or acquired bleeding disorders or hemorrhagic stroke or bleeding Subjects suffering from bleeding or other conditions related to hypocoagulability such as sexual shock, trauma, surgery or dysmenorrhea, or individuals who produce inhibitory antibodies against a procoagulant such as FVIII or FIX, or directly In individuals who have been administered excessive amounts of anticoagulants such as Xa or direct thrombin inhibitors or novel oral anticoagulants (NOACs), or individuals who have demonstrated unexplained bleeding Inducing synergistic benefits when used to treat or prevent bleeding or coagulation. The invention also relates to APC and other anticoagulant therapy as a result of, for example, overproduction of APC (such as through severe injury and / or hemorrhagic shock) or APC or other anticoagulant therapy in the treatment of inflammatory disorders or septic diseases. It relates to Super FVa alone or in combination with FVIIa or other clotting agents or hemostatic support agents to prevent, treat or reverse the associated bleeding. [Selection] Figure 1 |